The overexpression of ABCC2 primarily in endothelial cells of the hematoencephalic barrier, liver, intestine, kidney, placenta, and lungs has been reported to be a risk factor for the resistance to drugs used in epilepsy, cancer, and hepatitis [38,39]. Here, ABCC2 is linked to Hepatitis.